Not all cancers are the same, and neither should their treatment be. OncoHRD® by 1Cell.Ai is an advanced genomic test that detects Homologous Recombination Deficiency (HRD), a specific DNA repair defect found in breast, ovarian, prostate, and pancreatic cancers. By identifying this defect, OncoHRD® helps oncologists decide whether treatments like PARP inhibitors or platinum-based chemotherapy are the right fit for each patient, taking the guesswork out of critical treatment decisions.
For patients, this means a clearer path to therapies that are more likely to work for your specific cancer. For oncologists, it means actionable insights backed by deep sequencing of 50+ HRR genes, genomic scar analysis, and AI-powered reporting through the iCARE™ platform, all delivered with fast turnaround and clinical precision.
Our whitepaper dives deeper into the science, clinical evidence, and real-world impact of HRD testing in precision oncology. Whether you are a clinician looking to enhance treatment accuracy or a patient seeking the best possible care, this resource is designed for you. Download the OncoHRD® WhitePaper below to learn how smarter testing leads to better outcomes.